Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stabilization of vulnerable carotid atherosclerotic plaques by rivaroxaban assessed with 3D contrast-enhanced ultrasound
2020-001053-44Phase 4Active
- Sponsor
- Rigshospitalet
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Carotid artery disease (CAD) and atherosclerotic disease comparing Rivaroxaban with Placebo (2 arms). Started Apr 2020; status: active.
02
Drugs
rivaroxaban
03
Conditions
Carotid artery disease (CAD)atherosclerotic disease
Beyond the preview
Go deeper on 2020-001053-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001053-44.